John Mulligan
FounderFounder at Bonum Therapeutics · Founder at Good Therapeutics
Seattle, Washington, United States
Find your path to John
5,266 people in our graph share verified history with John — schools, employers, funds. One of them is your warm intro.
About
John Mulligan is the founder and CEO of Bonum Therapeutics, a spinout of Good Therapeutics developing protein drugs designed to activate under specific conditions. He previously served as CEO of Good Therapeutics until its acquisition by Roche in September 2022, and has been an early employee or founder at a synthetic biology company and several drug discovery companies, including Darwin Molecular and Glycostasis. His work spans drug discovery, genetics, and molecular biology, and in 2022 he co-founded Nagoon Therapeutics, a startup focused on antibody therapeutics for hematological malignancies.
Founder at Bonum Therapeutics
Intro paths
In turn, John can intro founders to Bonum Therapeutics's investors below.
Founder at Good Therapeutics
Intro paths
In turn, John can intro founders to Good Therapeutics's investors below.
Experience
- Bonum TherapeuticsFounder and CEOcurrent2022 — presentSeattle, Washington, United States
- Nagoon Therapeutics, Inc.Co-Foundercurrent2022 — presentSeattle, Washington, United States
- Good Therapeutics, Inc.Founder and CEO2016 — 2022Greater Seattle Area
- MicrosoftConsultant2015 — 2020Greater Seattle Area
- Pacific Northwest Diabetes Research InstituteScientist2013 — 2015Greater Seattle Area
- Glycostasis, Inc.Founder and CEO2012 — 2015Seattle, WA
- Cambrian GenomicsMolecular Biology Guru2012 — 2015Seattle / San Francisco
- Auxin Partners, LLCAssociate Partner2011 — 2012
- Blue Heron Biotech LLCFounder, President and CEO, and then CSO1999 — 2010
- Darwin MolecularDirector of Genomics1994 — 1998
- Stanford University School of MedicineResearch Assistant Professor1991 — 1994
- Stanford UniversityPostdoctoral Fellow1988 — 1991
Skills & more
+9 more
Drug DevelopmentDNA sequencingBiopharmaceuticalsClinical TrialsPatentsLaboratoryStrategySequencingCell CultureFrom John's professional profile.
Frequently asked questions
- Who is John Mulligan?
- John Mulligan is the founder and CEO of Bonum Therapeutics, a spinout of Good Therapeutics developing protein drugs designed to activate under specific conditions. He previously served as CEO of Good Therapeutics until its acquisition by Roche in September 2022, and has been an early employee or founder at a synthetic biology company and several drug discovery companies, including Darwin Molecular and Glycostasis. His work spans drug discovery, genetics, and molecular biology, and in 2022 he co-founded Nagoon Therapeutics, a startup focused on antibody therapeutics for hematological malignancies.
- Where does John Mulligan work?
- John Mulligan is Founder of Bonum Therapeutics and Co-founder at Good Therapeutics.
- What companies did John Mulligan found?
- John Mulligan founded Bonum Therapeutics, Good Therapeutics.
- Where did John Mulligan go to school?
- John Mulligan studied at Stanford University (PhD, Biology); Massachusetts Institute of Technology (Bachelor of Science, Biology).
Founder mafias
Stanford University mafia1,909
Also came through, then founded or led a company.
+ 1,902 more
Massachusetts Institute of Technology mafia1,211
Also came through, then founded or led a company.
+ 1,204 more
Bonum Therapeutics mafia2
Also came through, then founded or led a company.
Same school
Also attended Stanford University2,000
+ 1,994 more
Also attended Massachusetts Institute of Technology2,000
+ 1,994 more
Shared employers
Also worked at Good Therapeutics, Inc.1
Also worked at Microsoft1,827
+ 1,821 more
Also worked at Stanford University School of Medicine174
+ 168 more
Also worked at Stanford University1,030
+ 1,024 more